Risperidone Patent Expiration

Risperidone is used for treating various conditions such as depression, anxiety, and obsessive-compulsive disorder. It was first introduced by Janssen Pharmaceuticals Inc in its drug Risperdal on Dec 29, 1993. Other drugs containing Risperidone are Risperdal Consta, Rykindo, Risvan, Perseris Kit, Uzedy. 45 different companies have introduced drugs containing Risperidone.


Risperidone Patents

Given below is the list of patents protecting Risperidone, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Uzedy US12128132 Drug delivery formulations Sep 11, 2040 Teva
Uzedy US9023897 Biodegradable drug delivery compositions Apr 05, 2033 Teva
Rykindo US10098882 Risperidone sustained release microsphere composition Apr 10, 2032 Shandong Luye
Rykindo US10406161 Risperidone sustained release microsphere composition Apr 10, 2032 Shandong Luye
Rykindo US11110094 Risperidone sustained release microsphere composition Apr 10, 2032 Shandong Luye
Rykindo US9446135 Risperidone sustained release microsphere composition Apr 10, 2032 Shandong Luye
Rykindo US9532991 Risperidone sustained release microsphere composition Apr 10, 2032 Shandong Luye
Risvan US10058504 Methods for the preparation of injectable depot compositions May 31, 2031 Labs Farms Rovi Sa
Risvan US10085936 Antipsychotic injectable depot composition May 31, 2031 Labs Farms Rovi Sa
Risvan US10182982 Antipsychotic injectable depot composition May 31, 2031 Labs Farms Rovi Sa
Risvan US10195138 Methods for the preparation of injectable depot compositions May 31, 2031 Labs Farms Rovi Sa
Risvan US10335366 Risperidone or paliperidone implant formulation May 31, 2031 Labs Farms Rovi Sa
Risvan US10463607 Antipsychotic Injectable Depot Composition May 31, 2031 Labs Farms Rovi Sa
Risvan US10881605 Methods for the preparation of injectable depot compositions May 31, 2031 Labs Farms Rovi Sa
Risvan US11007139 Risperidone or paliperidone implant formulation May 31, 2031 Labs Farms Rovi Sa
Risvan US11173110 Risperidone or paliperidone implant formulation May 31, 2031 Labs Farms Rovi Sa
Risvan US11241377 Antipsychotic injectable depot composition May 31, 2031 Labs Farms Rovi Sa
Risvan US11752092 Methods for the preparation of injectable depot compositions May 31, 2031 Labs Farms Rovi Sa
Risvan US11752093 Antipsychotic injectable depot composition May 31, 2031 Labs Farms Rovi Sa
Risvan US11752094 Antipsychotic injectable depot composition May 31, 2031 Labs Farms Rovi Sa
Risvan US11759416 Antipsychotic injectable depot composition May 31, 2031 Labs Farms Rovi Sa
Perseris Kit US10010612 Sustained delivery formulations of risperidone compounds Feb 13, 2028 Indivior
Perseris Kit US10376590 Sustained delivery formulations of risperidone compound Feb 13, 2028 Indivior
Perseris Kit US11013809 Sustained delivery formulations of risperidone compound Feb 13, 2028 Indivior
Perseris Kit US11712475 Sustained delivery formulations of risperidone compound Feb 13, 2028 Indivior
Perseris Kit US9180197 Sustained delivery formulations of risperidone compounds Feb 13, 2028 Indivior
Perseris Kit US9186413 Sustained delivery formulations of risperidone compounds Feb 13, 2028 Indivior
Uzedy US8221778 Drug-containing implants and methods of use thereof Nov 12, 2027 Teva
Uzedy US8741327 Method of maintaining therapeutic risperidone levels in a PLA:PLGA implant Nov 12, 2027 Teva
Perseris Kit US11110093 Sustained release small molecule drug formulation Nov 05, 2026 Indivior
Perseris Kit US10058554 Sustained release small molecule drug formulation Sep 26, 2026 Indivior
Perseris Kit US9597402 Sustained release small molecule drug formulation Sep 26, 2026 Indivior
Perseris Kit US10406160 Sustained release small molecule drug formulation Jun 26, 2026 Indivior
Uzedy US10736965 Risperidone biodegradable implant Jan 12, 2025

(Expired)

Teva
Uzedy US8802127 Risperidone-containing PLA:PGA implants and methods of use thereof Jan 12, 2025

(Expired)

Teva
Uzedy US9439905 Risperidone-containing implants and methods of use thereof Jan 12, 2025

(Expired)

Teva
Uzedy US9717799 Drug-containing implants and methods of use thereof Jan 12, 2025

(Expired)

Teva
Uzedy US9895447 Drug-containing PLA implants and methods of use thereof Jan 12, 2025

(Expired)

Teva
Uzedy US9925268 Drug-containing implants and methods of use thereof Jan 12, 2025

(Expired)

Teva
Risperdal Consta US6667061

(Pediatric)

Preparation of injectable suspensions having improved injectability Nov 25, 2020

(Expired)

Janssen Pharms
Risperdal Consta US6667061 Preparation of injectable suspensions having improved injectability May 25, 2020

(Expired)

Janssen Pharms
Risperdal Consta US6194006

(Pediatric)

Preparation of microparticles having a selected release profile Jun 30, 2019

(Expired)

Janssen Pharms
Risperdal Consta US6379703

(Pediatric)

Preparation of microparticles having a selected release profile Jun 30, 2019

(Expired)

Janssen Pharms
Risperdal Consta US6596316

(Pediatric)

Preparation of microparticles having a selected release profile Jun 30, 2019

(Expired)

Janssen Pharms
Risperdal Consta US6194006 Preparation of microparticles having a selected release profile Dec 30, 2018

(Expired)

Janssen Pharms
Risperdal Consta US6379703 Preparation of microparticles having a selected release profile Dec 30, 2018

(Expired)

Janssen Pharms
Risperdal Consta US6596316 Preparation of microparticles having a selected release profile Dec 30, 2018

(Expired)

Janssen Pharms
Risperdal US6224905

(Pediatric)

Biconvex rapidly disintegrating dosage forms Dec 10, 2017

(Expired)

Janssen Pharms
Risperdal Consta US5792477

(Pediatric)

Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent Nov 02, 2017

(Expired)

Janssen Pharms
Risperdal Consta US5916598

(Pediatric)

Preparation of biodegradable, biocompatible microparticles containing a biologically active agent Nov 02, 2017

(Expired)

Janssen Pharms
Risperdal Consta US6403114

(Pediatric)

Preparation of biodegradable, biocompatible microparticles containing a biologically active agent Nov 02, 2017

(Expired)

Janssen Pharms
Risperdal US6224905 Biconvex rapidly disintegrating dosage forms Jun 10, 2017

(Expired)

Janssen Pharms
Risperdal Consta US5792477 Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent May 02, 2017

(Expired)

Janssen Pharms
Risperdal Consta US5916598 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent May 02, 2017

(Expired)

Janssen Pharms
Risperdal Consta US6403114 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent May 02, 2017

(Expired)

Janssen Pharms
Risperdal Consta US5688801

(Pediatric)

Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles May 18, 2015

(Expired)

Janssen Pharms
Risperdal US5648093

(Pediatric)

Pharmaceutical and other dosage forms Jan 15, 2015

(Expired)

Janssen Pharms
Risperdal US5453425

(Pediatric)

Risperidone oral formulation Jan 11, 2015

(Expired)

Janssen Pharms
Risperdal USRE39181

(Pediatric)

Aqueous risperidone formulations Jan 11, 2015

(Expired)

Janssen Pharms
Risperdal Consta US5688801 Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles Nov 18, 2014

(Expired)

Janssen Pharms
Risperdal US5648093 Pharmaceutical and other dosage forms Jul 15, 2014

(Expired)

Janssen Pharms
Risperdal US5453425 Risperidone oral formulation Jul 11, 2014

(Expired)

Janssen Pharms
Risperdal USRE39181 Aqueous risperidone formulations Jul 11, 2014

(Expired)

Janssen Pharms
Risperdal Consta US5965168

(Pediatric)

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles May 19, 2014

(Expired)

Janssen Pharms
Risperdal Consta US6110921

(Pediatric)

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles May 19, 2014

(Expired)

Janssen Pharms
Risperdal Consta US6368632

(Pediatric)

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles May 19, 2014

(Expired)

Janssen Pharms
Risperdal Consta US7547452

(Pediatric)

Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles May 19, 2014

(Expired)

Janssen Pharms
Risperdal Consta US5965168 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles Nov 19, 2013

(Expired)

Janssen Pharms
Risperdal Consta US6110921 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles Nov 19, 2013

(Expired)

Janssen Pharms
Risperdal Consta US6368632 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles Nov 19, 2013

(Expired)

Janssen Pharms
Risperdal Consta US7547452 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles Nov 19, 2013

(Expired)

Janssen Pharms



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Risperidone's patents.

Given below is the list recent legal activities going on the following patents of Risperidone.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 03 Jul, 2024 US9532991
Surcharge for Late Payment, Large Entity 17 Apr, 2024 US10736965
Payment of Maintenance Fee, 4th Year, Large Entity 17 Apr, 2024 US10736965
Maintenance Fee Reminder Mailed 01 Apr, 2024 US10736965
Payment of Maintenance Fee, 8th Year, Large Entity 19 Mar, 2024 US9446135
Payment of Maintenance Fee, 8th Year, Large Entity 28 Feb, 2024 US9439905
Payment of Maintenance Fee, 12th Yr, Small Entity 03 Jan, 2024 US8221778
Payment of Maintenance Fee, 4th Year, Large Entity 10 Mar, 2023 US10406161
Payment of Maintenance Fee, 8th Year, Large Entity 02 Nov, 2022 US9023897
Payment of Maintenance Fee, 4th Year, Large Entity 28 Mar, 2022 US10098882


Risperidone's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Risperidone Generic API Manufacturers

Several generic applications have been filed for Risperidone. The first generic version for Risperidone was by Heritage Pharma Labs Inc Dba Avet Pharmaceuticals Labs Inc and was approved on Jun 30, 2008. And the latest generic version is by Ipca Laboratories Ltd and was approved on Jun 26, 2024.

Given below is the list of companies who have filed for Risperidone generic, along with the locations of their manufacturing plants worldwide.


Risperidone News

New Lawsuit Claims Widely Used Medication Led to Patient's Breast Cancer - CounterPunch.org

13 Aug, 2025

See More